Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROKETAZINE vs ATIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Nausea and vomiting,Antipsychotic (off-label),Sedation (off-label)
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Terminal elimination half-life is 15-20 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Hepatic via CYP2D6 and other cytochrome P450 enzymes.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Primarily renal excretion of metabolites; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 20% of total clearance.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
Volume of distribution is 20-30 L/kg, indicating extensive tissue distribution and high lipophilicity.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
Oral bioavailability is 30-40% due to extensive first-pass metabolism. IM bioavailability is approximately 70%.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
GFR 30-50 m L/min: reduce dose by 25%; GFR <30 m L/min: reduce dose by 50% and extend interval to every 12 hours.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 50 mg per day for children <12 years.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
Initial dose 12.5 mg intramuscularly; maximum 50 mg per day; monitor for anticholinergic effects and sedation.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
Increased risk of death in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
May cause QT prolongation, neuroleptic malignant syndrome, tardive dyskinesia, hypotension, and increased risk of falls. Use with caution in patients with cardiovascular disease, seizures, or hepatic impairment.
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Hypersensitivity to phenothiazines, severe CNS depression, comatose states, and blood dyscrasias.
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
Avoid grapefruit juice as it may inhibit metabolism and increase toxicity. Avoid high-tyramine foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis if used with MAOIs.
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third trimesters: Possible extrapyramidal symptoms and neonatal withdrawal in newborns after maternal use near term. Use only if benefit outweighs risk.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
Prochlorperazine is excreted into human breast milk in low amounts. Milk/plasma (M/P) ratio is approximately 1.0. Potential for adverse effects in nursing infants, including sedation and extrapyramidal symptoms. Caution advised; monitor infant for drowsiness and EPS.
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
Pregnancy may increase clearance of prochlorperazine due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed; consider lower initial doses and titrate based on clinical response. No specific pharmacokinetic data in pregnancy; use minimum effective dose.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
Monitor for extrapyramidal symptoms, especially in elderly and pediatric patients. Proketazine may cause significant hypotension; avoid rapid IV administration. Contraindicated in patients with bone marrow suppression or severe hepatic impairment.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
Avoid alcohol and CNS depressants as they may increase sedation.,Report any involuntary muscle movements or stiffness immediately.,Rise slowly from sitting or lying to prevent dizziness.,May cause dry mouth; use sugar-free gum or candy.,Do not discontinue abruptly without consulting prescriber.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROKETAZINE vs ATIVAN, answered by our medical review team.
PROKETAZINE is a Phenothiazine Antipsychotic that works by Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.. ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROKETAZINE and ATIVAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROKETAZINE is: 25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.. The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROKETAZINE and ATIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROKETAZINE is classified as Category C. PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third t. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.